|
Post by agedhippie on May 15, 2017 9:11:13 GMT -5
Interesting Amgen issued notes which netted 3.5 billion and issued a CTO on 5/8 just a coincidence that is when we went from .80 to 1.87? What does Amgen need 3.5 billion for? Mnkd issues change of control parachute, CTO on 4/26, announce moving headquarters 50 miles down the road just happens to be close to Amgen, announce middle East approval but stay tuned, could we have sold middle East rights or international rights? First time in a couple years my gut is telling me load up the truck with cheap shares. What it tells you is to read the prospectus. The money is to roll-over debt, and fund their stock repurchase. Amgen used to have an interest in diabetes but they got out of that market years ago. Their current and very profitable focus is nowhere near diabetes. The idea that Amgen would buy Mannkind is a fantasy. So lets fantasize - if Amgen want Mannkind then I think it would be as a delivery vehicle for their drugs, they would probably dump Afrezza since it doesn't fit and isn't profitable. The question is whether they want to go through the argument over lung issues and it's impact on sales. The change of control parachute was just what Matt said, it was bringing the execs into line with the old 2013 change of control agreement since almost all those execs have left now. I suggest taking some Tums and postponing the truck if you are relying on Amgen buying Mannkind.
|
|
|
Post by mnkdnewbie on May 15, 2017 9:19:32 GMT -5
Interesting Amgen issued notes which netted 3.5 billion and issued a CTO on 5/8 just a coincidence that is when we went from .80 to 1.87? What does Amgen need 3.5 billion for? Mnkd issues change of control parachute, CTO on 4/26, announce moving headquarters 50 miles down the road just happens to be close to Amgen, announce middle East approval but stay tuned, could we have sold middle East rights or international rights? First time in a couple years my gut is telling me load up the truck with cheap shares. What it tells you is to read the prospectus. The money is to roll-over debt, and fund their stock repurchase. Amgen used to have an interest in diabetes but they got out of that market years ago. Their current and very profitable focus is nowhere near diabetes. The idea that Amgen would buy Mannkind is a fantasy. So lets fantasize - if Amgen want Mannkind then I think it would be as a delivery vehicle for their drugs, they would probably dump Afrezza since it doesn't fit and isn't profitable. The question is whether they want to go through the argument over lung issues and it's impact on sales. The change of control parachute was just what Matt said, it was bringing the execs into line with the old 2013 change of control agreement since almost all those execs have left now. I suggest taking some Tums and postponing the truck if you are relying on Amgen buying Mannkind. "Amgen used to have an interest in diabetes but they got out of that market years ago. Their current and very profitable focus is nowhere near diabetes" Just curious if Amgen had a booth at 2016 ADA, cause they have 2 near entrances at the 2017 ada.
|
|
|
Post by kimi on May 15, 2017 9:40:28 GMT -5
|
|
|
Post by matt on May 15, 2017 9:44:37 GMT -5
"Amgen used to have an interest in diabetes but they got out of that market years ago. Their current and very profitable focus is nowhere near diabetes" Just curious if Amgen had a booth at 2016 ADA, cause they have 2 near entrances at the 2017 ada. I expect they did, and not because they were interested in diabetes. Certain diseases appear together and diabetes comes with its close relatives cardiovascular disease and kidney failure, both of which are markets where Amgen has a major presence. Their very first product back in the 1980's was erythropoietin which is used to treat anemia, a frequent side effect of kidney failure. More recently Amgen has been trying to build a market for the first PCKS9 inhibitor, Repatha, used to treat high cholesterol levels that do not respond to statin drugs. Since Repatha sells for about $14 thousand a year it is a high potential drug for Amgen. Given the increasing difficulty of getting salesmen through the office door to actually call on physicians, any convention that has a large number of potential prescribers for any drug in the portfolio is fair game. While the ADA meeting might be about diabetes, the exhibition floor is about moving drugs and the exhibitors are not limited to drugs that treat diabetes itself.
|
|
|
Post by scanderson1961 on May 15, 2017 10:21:12 GMT -5
My thoughts on the "shipment": 1) I find it highly unlikely that any Afrezza has shipped internationally as of yet. Primarily because as Matt pointed out, they aren't approved anywhere yet. For a potential partner to place an order worth millions of dollars to purchase a product that has not been approved simply isn't logical. You don't assume that much risk as a business. Any potential buyer would simply wait for approval before buying in order to ensure that their purchased product is assured to have marketability. Businesses are just that, businesses. They are not casinos and typically avoid such risk and rarely, if ever, put the proverbial cart before the horse. 2) MNKD listed Afrezza sales of approximately $1.2 million for the last quarter if memory serves correct without checking the 10-Q. That most certainly would not include an order of that size if it had indeed shipped. Granted, the "discovery" was found after the new quarter would have started but MNKD has given zero indication that any new sales of Afrezza have taken place aside from the tepid script numbers that we see every week. 3) There is absolutely ZERO evidence that Amgen is involved in any way in this. Amgen's involvement has been debunked before. There is also been no indication of any foreign partnership, although I'll admit that MNKD will need one in order to distribute internationally. My bet is on a regional or national player in the area where they are on file. This is of course assuming approval, which they haven't received yet. In sum, there's entirely too much speculation on something that hasn't even been confirmed. I agree that this was likely the cause for the run up last week, much to the disbelief of some posters here. I also believe that the failure of this to be confirmed is the cause of the huge sell off on Friday. We shall see. Very logical. But Kuka and sayhey say Amgen is buying Mnkd and they are resident experts. Aren't they? They are well aware of Amgen business?
|
|
|
Post by kuka on May 15, 2017 10:39:53 GMT -5
AMGEN likes to make money ...that is their business model. They know Diabetes is growing every year especially in the Middle East.
Do you think they are just going to ignore that disease for some reason.
They are the BIGGEST Pharma in the world.... Duh
|
|
|
Post by silentknight on May 15, 2017 10:40:38 GMT -5
My thoughts on the "shipment": 1) I find it highly unlikely that any Afrezza has shipped internationally as of yet. Primarily because as Matt pointed out, they aren't approved anywhere yet. For a potential partner to place an order worth millions of dollars to purchase a product that has not been approved simply isn't logical. You don't assume that much risk as a business. Any potential buyer would simply wait for approval before buying in order to ensure that their purchased product is assured to have marketability. Businesses are just that, businesses. They are not casinos and typically avoid such risk and rarely, if ever, put the proverbial cart before the horse. 2) MNKD listed Afrezza sales of approximately $1.2 million for the last quarter if memory serves correct without checking the 10-Q. That most certainly would not include an order of that size if it had indeed shipped. Granted, the "discovery" was found after the new quarter would have started but MNKD has given zero indication that any new sales of Afrezza have taken place aside from the tepid script numbers that we see every week. 3) There is absolutely ZERO evidence that Amgen is involved in any way in this. Amgen's involvement has been debunked before. There is also been no indication of any foreign partnership, although I'll admit that MNKD will need one in order to distribute internationally. My bet is on a regional or national player in the area where they are on file. This is of course assuming approval, which they haven't received yet. In sum, there's entirely too much speculation on something that hasn't even been confirmed. I agree that this was likely the cause for the run up last week, much to the disbelief of some posters here. I also believe that the failure of this to be confirmed is the cause of the huge sell off on Friday. We shall see. Very logical. But Kuka and sayhey say Amgen is buying Mnkd and they are resident experts. Aren't they? They are well aware of Amgen business? One in particular also predicted a run up in advance of the shareholder meeting. We're currently down more than 25% since that prediction. Need I say more?
|
|
|
Post by kc on May 15, 2017 11:26:51 GMT -5
I am not convinced of anything at this time. You don't know how the folks in the UAE even work. It might be a local drug distribution Pharma in the UAE market buying a license to market and sell Afrezza directly to the Single Payer health care system. Do we know how the system works in the UAE. We can't assume its like the US distribution of drugs with Insurance and co-pay. I don't know but believe its run by the Government there.
|
|
|
Post by dreamboatcruise on May 15, 2017 11:32:50 GMT -5
Interesting Amgen issued notes which netted 3.5 billion and issued a CTO on 5/8 just a coincidence that is when we went from .80 to 1.87? What does Amgen need 3.5 billion for? Mnkd issues change of control parachute, CTO on 4/26, announce moving headquarters 50 miles down the road just happens to be close to Amgen, announce middle East approval but stay tuned, could we have sold middle East rights or international rights? First time in a couple years my gut is telling me load up the truck with cheap shares. If I've learned one thing as a MNKD investor for many years now, it's kinda like a trip to a third world country... lots of unbelievable things to see, but not viable for retirement, and if your gut starts getting that strange feeling, stop eating immediately no matter how good it seems to taste.
|
|
|
Post by dreamboatcruise on May 15, 2017 11:35:35 GMT -5
I am not convinced of anything at this time. You don't know how the folks in the UAE even work. It might be a local drug distribution Pharma in the UAE market buying a license to market and sell Afrezza directly to the Single Payer health care system. Do we know how the system works in the UAE. We can't assume its like the US distribution of drugs with Insurance and co-pay. I don't know but believe its run by the Government there. If one is assuming that this shipment is real, one might as well assume whatever they think is most beneficial regarding all the other details. When it comes to dreams, one should dream big or go home.
|
|
|
Post by madog365 on May 15, 2017 11:42:04 GMT -5
I am not convinced of anything at this time. You don't know how the folks in the UAE even work. It might be a local drug distribution Pharma in the UAE market buying a license to market and sell Afrezza directly to the Single Payer health care system. Do we know how the system works in the UAE. We can't assume its like the US distribution of drugs with Insurance and co-pay. I don't know but believe its run by the Government there. Daman is a non-life insurance conventional health insurance government-affiliated company in Abu Dhabi, United Arab Emirates. It started operations in May 2006, with over 1000 employees. Mohammed Sultan bin Ghanoum Al Hameli is the chairman and Dr. Michael Bitzer is the CEO of Daman. Daman offers a range of health insurance plans with added benefits, extended policy limits and wider geographical coverage. Daman is a public joint-stock company that is 80% owned by the Abu Dhabi Government with the remaining 20% owned by the Germany based Munich Re. With the highest market share in Abu Dhabi, Daman covers more than 2,600,000 members One Drop & Daman mhealth.ae/onedrop/
|
|
|
Post by kc on May 15, 2017 14:05:37 GMT -5
I am not convinced of anything at this time. You don't know how the folks in the UAE even work. It might be a local drug distribution Pharma in the UAE market buying a license to market and sell Afrezza directly to the Single Payer health care system. Do we know how the system works in the UAE. We can't assume its like the US distribution of drugs with Insurance and co-pay. I don't know but believe its run by the Government there. Daman is a non-life insurance conventional health insurance government-affiliated company in Abu Dhabi, United Arab Emirates. It started operations in May 2006, with over 1000 employees. Mohammed Sultan bin Ghanoum Al Hameli is the chairman and Dr. Michael Bitzer is the CEO of Daman. Daman offers a range of health insurance plans with added benefits, extended policy limits and wider geographical coverage. Daman is a public joint-stock company that is 80% owned by the Abu Dhabi Government with the remaining 20% owned by the Germany based Munich Re. With the highest market share in Abu Dhabi, Daman covers more than 2,600,000 members One Drop & Daman mhealth.ae/onedrop/I am very impressed with this bit of research. Very good work. I like the connections and tie-in to the UAE with Daman.
|
|
|
Post by cyn on May 15, 2017 14:20:12 GMT -5
Great find madog! Many Thanks!
Madog writes... One Drop & Daman
mhealth.ae/onedrop/
|
|
|
Post by cyn on May 15, 2017 14:40:45 GMT -5
I am not convinced of anything at this time. You don't know how the folks in the UAE even work. It might be a local drug distribution Pharma in the UAE market buying a license to market and sell Afrezza directly to the Single Payer health care system. Do we know how the system works in the UAE. We can't assume its like the US distribution of drugs with Insurance and co-pay. I don't know but believe its run by the Government there. Daman is a non-life insurance conventional health insurance government-affiliated company in Abu Dhabi, United Arab Emirates. It started operations in May 2006, with over 1000 employees. Mohammed Sultan bin Ghanoum Al Hameli is the chairman and Dr. Michael Bitzer is the CEO of Daman. Daman offers a range of health insurance plans with added benefits, extended policy limits and wider geographical coverage. Daman is a public joint-stock company that is 80% owned by the Abu Dhabi Government with the remaining 20% owned by the Germany based Munich Re. With the highest market share in Abu Dhabi, Daman covers more than 2,600,000 members One Drop & Daman mhealth.ae/onedrop/For more insight on partnership between Daman and One Drop, see PR Newswire dated Dec 2016 .... www.prnewswire.com/news-releases/one-drop-announces-partnership-with-the-national-health-insurance-company--daman-the-uaes-leading-specialized-health-insurer-and-implementation-of-one-drop--professional-enterprise-platform-300378526.html
Quote from Daman CEO, Michael Bitzer states, "We are committed to using the most innovative technology to expand quality and effectiveness of care, and through our partnership with One Drop we expect to make great strides in diabetes management and outcomes."
|
|
|
Post by hans on May 15, 2017 14:50:29 GMT -5
So now we're waiting on this MOU between MNKD and One Drop to become an agreement.
|
|